References
Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M (2005) Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch (in press)
Brenner BM, Grunfeld JP (2004) Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 13:231–241
Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629–632
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International Collaborative Fabry Disease Study Group (2001) Safety and efficacy of recombinant human it alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Politei, J. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1–7. Virchows Arch 448, 873 (2006). https://doi.org/10.1007/s00428-006-0170-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-006-0170-0